Company Nile Therapeutics, Inc. Other OTC
Equities
US6541451018
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-13 | Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 | |
05-13 | Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q1 Revenue $4.9M, vs. Street Est of $9.7M | MT |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Transformative Cell and Exosome-based Therapeutics
100.0
%
| 3 | 100.0 % | 25 | 100.0 % | +886.81% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 3 | 100.0 % | 25 | 100.0 % | +886.81% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 13-11-19 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 13-11-19 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Karen Krasney
LAW | General Counsel | 71 | 11-12-31 |
General Counsel | 71 | 15-02-27 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 23-07-20 |
Earl Collier
BRD | Director/Board Member | 76 | 13-11-19 |
George Dunbar
BRD | Director/Board Member | 77 | 13-11-19 |
David Musket
BRD | Director/Board Member | 66 | 13-11-19 |
Frank Litvack
CHM | Chairman | 68 | 11-12-31 |
Karimah Es Sabar
BRD | Director/Board Member | 66 | 21-07-22 |
Linda Marbán
CEO | Chief Executive Officer | 60 | 13-11-19 |
Paul Auwaerter
BRD | Director/Board Member | 62 | 23-07-12 |
Michael Kelliher
BRD | Director/Board Member | 47 | 23-08-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 31,811,470 | 28,874,629 ( 90.77 %) | 0 | 90.77 % |
Company contact information
Capricor Therapeutics, Inc.
10865 Road to the Cure Suite 150
92121, San Diego
+858 727 1755
http://www.capricor.comSector
1st Jan change | Capi. | |
---|---|---|
+7.52% | 113B | |
+11.38% | 106B | |
+1.02% | 22.27B | |
-12.64% | 22.22B | |
-5.29% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+7.77% | 14.29B | |
+37.41% | 12.52B |
- Stock Market
- Equities
- CAPR Stock
- Stock
- Company Nile Therapeutics, Inc.